$AIMD

Ainos, Inc. (NASDAQ:AIMD) said its AI Nose platform surpassed 878 million real-world smell and chemical data points, up from about 613 million on July 21, adding about 265 million in 23 days. The company links the growth to continued deployment of 1,400 AI Nose systems at semiconductor customer sites and its ScentAI continuous learning approach.

Ainos, Inc. (NASDAQ:AIMD) said VASRO GmbH published a report on scaling its AI Nose platform. VASRO cited about 613 million industrial Smell ID records accumulated since Dec. 2025 and a $2.1 million AI Nose subscription backlog from a backend semiconductor customer, including $350,000 prepaid. The report points to validation in semiconductor fabs and potential revenue growth in H2 2026.

Ainos, Inc. (NASDAQ:AIMD) reported second-quarter 2026 results for the quarter ended June 30 and updated investors on AI Nose deployments. The company said AI Nose expanded across semiconductor manufacturing, industrial and healthcare infrastructure, and robotics, building smell data. It cited about 613 million industrial smell records accumulated since Dec. 2025, and referenced an initial $2.1 million commercial arrangement.

Ainos, Inc. (AIMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Ainos Reports Second Quarter 2026 Results and Highlights Continued AI Nose Execution Across Industrial, Healthcare Infrastructure and Robotics Markets Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) (“Ainos” or the “Company”) today announced resu

Ainos, Inc. (NASDAQ:AIMD) said its AI Nose deployments have generated about 613 million industrial scent data points since December 2025, mainly from semiconductor manufacturing. The company says the data supports its Smell AI platform by refining proprietary Smell IDs and its Smell Language Model, and it plans to expand into other industries.

Ainos, Inc. (AIMD) filed an SEC Form 8-K — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. false 0001014763 0001014763 2026-07-03 2026-07-03 0001014763 AIMD:CommonStockParValue0.01PerShareMember 2026-07-03 2026-07-03 0001014763 AIMD:WarrantsToPurchaseCommonStockMember 2026-07-03 2026-07-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND E

Ainos, Inc. (NASDAQ:AIMD) said VASRO GmbH reviewed its planned expansion of the AI Nose platform into patient-level breath intelligence. The VASRO update covers a one-year research program with National Taiwan University starting July 1, 2026, to test whether AI-analyzed breath patterns can distinguish acute COPD exacerbations from acute decompensated heart failure.

chiang yao-chung purchased 3,500 indirectly-held shares of Ainos, Inc. (AIMD) at $2.05 on 2026-06-05.

chiang yao-chung purchased 2,000 indirectly-held shares of Ainos, Inc. (AIMD) at $2.13 on 2026-06-03.

Ainos, Inc. (NASDAQ:AIMD) said VASRO GmbH highlighted its AI Nose platform’s expansion into live emergency department operations. VASRO reports a research program at an Asia academic medical center to generate 2,500+ hours of emergency-department environmental scent data for overcrowding early warning and respiratory infection risk analysis. The initiative broadens evaluations beyond industrial settings and supports Ainos’ Smell Language Model development.